Duesseldorf, April 18, 2023 – Today, the management board of Gerresheimer AG (ISIN DE000A0LD6E6), with the approval of the supervisory board, resolved to launch a capital increase against cash contributions under exclusion of shareholder’s subscription rights through partial utilization of its authorized capital. The share capital of the company will be increased by issuance of up to 3,140,000 new no-par-value bearer shares.
The private placement will commence with immediate effect after publication of this notification and the new shares will be offered exclusively to institutional investors as part of an international private placement by way of an accelerated bookbuilding process. The placement price and the number of shares to be issued will be determined immediately after such bookbuilding. The new shares will carry full rights to the dividend of EUR 1.25 per share proposed for the 2021/2022 financial year.
Admission of the new shares to trading in the sub-segment of the regulated market with additional post-admission obligations (Prime Standard) on the Frankfurt Stock Exchange is expected to take place without a prospectus on April 21, 2023. Trading is expected to commence on April 24, 2023. It is intended to include the new shares in the existing quotation for the Company's shares. The delivery of the new shares is expected to occur on or around April 24, 2023.
The successful implementation of Gerresheimer’s strategy for profitable growth – formula G – is bearing fruits. It is not only resulting in double digit growth rates for both revenues and Adjusted EBITDA, but also in better access to further, highly profitable growth projects to sustainably increase the company value. The net proceeds from the capital increase will provide the company with the flexibility to further capture significant incremental growth opportunities with a particular focus on High Value Solutions and Medical Devices including biological solutions such as GLP-1 related treatments.
As part of the transaction, Gerresheimer has agreed to a lock-up, i.e., an obligation not to, inter alia, issue further shares or financial instruments convertible into shares or to conduct a further capital increase of 180 days, subject to customary exceptions.
Contact Press
Ueli Utzinger
Group Senior Director Marketing & Communications
T +41 79 400 86 40
ueli.utzinger@gerresheimer.com
Contact Investor Relations
Carolin Nadilo
Corporate Senior Director Investor Relations
T +49 211 6181-220
carolin.nadilo@gerresheimer.com
Christian Lösse
Senior Manager Investor Relations
T +49 211 61 81-314
christian.loesse@gerresheimer.com
About Gerresheimer
Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 11,000 employees and generated annual revenues in 2022 of EUR 1.82bn. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.
www.gerresheimer.com
